We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+8.23%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.74B
AUM Growth
-$74.6M
Cap. Flow
-$193M
Cap. Flow %
-5.15%
Top 10 Hldgs %
49.32%
Holding
151
New
26
Increased
20
Reduced
26
Closed
34

Top Buys

Rank Stock Value
1
CRNX
Crinetics Pharmaceuticals
CRNX
+$76.8M
2
ATNX
Athenex, Inc. Common Stock
ATNX
+$47.1M
3
VRAY
ViewRay, Inc.
VRAY
+$35.6M
4
ARNA
Arena Pharmaceuticals Inc
ARNA
+$21.3M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$20.4M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$65.3M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$64.5M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$57.5M
4
HUM icon
Humana
HUM
+$36.8M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$35.2M

Sector Composition

Rank Sector Weight
1 Healthcare 93.11%
2 Miscellaneous 5.71%
3 Consumer Staples 0.92%
4 Financials 0.17%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABEO icon
76
Abeona Therapeutics
ABEO
$313M
$3.08M 0.08%
9,618
+7,232
+303% +$2.57M
NVTR
77
DELISTED
Nuvectra Corporation Common Stock
NVTR
$2.97M 0.08%
135,000
-24,466
-15% -$471K
IVC
78
DELISTED
Invacare Corporation
IVC
$2.91M 0.08%
200,000
– –
ALNA
79
DELISTED
Allena Pharmaceuticals
ALNA
$2.69M 0.07%
250,000
– –
ARVN icon
80
Arvinas
ARVN
$540M
$2.11M 0.06%
+125,000
New +$2.06M
VERU icon
81
Veru
VERU
$39.9M
$2.02M 0.05%
+142,500
New +$2.79M
ODT
82
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$1.94M 0.05%
100,000
-50,000
-33% -$1.02M
EIGR
83
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.89M 0.05%
5,256
– –
KNSA icon
84
Kiniksa Pharmaceuticals
KNSA
$5.86B
$1.36M 0.04%
53,169
-57,942
-52% -$1.13M
TRHC
85
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
$1.19M 0.03%
14,663
– –
VKTX icon
86
Viking Therapeutics
VKTX
$3.49B
$1.12M 0.03%
+64,261
New +$765K
STLA icon
87
Stellantis
STLA
$14.8B
$1.09M 0.03%
62,000
– –
ONC
88
BeOne Medicines Ltd
ONC
$39.2B
$982K 0.03%
5,700
– –
ADYX
89
DELISTED
Adynxx Inc
ADYX
$961K 0.03%
70,566
– –
SNDA icon
90
Sonida Senior Living
SNDA
$1.91B
$946K 0.03%
6,678
– –
PTCT icon
91
PTC Therapeutics
PTCT
$5.48B
$910K 0.02%
19,367
– –
RACE icon
92
Ferrari
RACE
$71.5B
$849K 0.02%
6,200
– –
RETA
93
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$791K 0.02%
+9,677
New +$682K
GTHX
94
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$735K 0.02%
14,055
– –
ICPT
95
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$711K 0.02%
+5,627
New +$595K
OCGN icon
96
Ocugen
OCGN
$337M
$656K 0.02%
20,057
-16,664
-45% -$1.93M
MNTA
97
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$644K 0.02%
24,489
– –
NTRA icon
98
Natera
NTRA
$50.6B
$575K 0.02%
+24,000
New +$580K
SENS icon
99
Senseonics Holdings Inc
SENS
$470M
$549K 0.01%
5,750
– –
BLFS icon
100
BioLife Solutions
BLFS
$1.78B
$514K 0.01%
+29,376
New +$581K
2 3
4
5 6

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q3 2018 Portfolio in Review

As of Q3 2018, Perceptive Advisors held 151 positions worth $3.74B, down 2% from $3.81B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Perceptive Advisors withdrew a net $193M in Q3 2018, closing 34 positions and reducing 26 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $57.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Perceptive Advisors opened a new position in Crinetics Pharmaceuticals worth $74.1M.

  • Perceptive Advisors's largest Q3 2018 buy was Crinetics Pharmaceuticals: 2,587,953 shares worth $74.1M.
  • Perceptive Advisors added most to Athenex, Inc. Common Stock in Q3 2018, an estimated $47.1M increase.
  • Perceptive Advisors's biggest Q3 2018 reduction was Alnylam Pharmaceuticals, cutting an estimated $65.3M.
  • Perceptive Advisors fully exited Alexion Pharmaceuticals in Q3 2018, selling an estimated $57.5M.
  • Perceptive Advisors's ten largest holdings make up 49% of its $3.74B portfolio in Q3 2018.
  • Perceptive Advisors opened 26 new positions and closed 34 in Q3 2018.
  • Perceptive Advisors's portfolio value fell 2% quarter-over-quarter to $3.74B.

Based on Perceptive Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.